Fosamprenavir and Buprenorphine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Fosamprenavir
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Fosamprenavir (Lexiva) is an HIV medicine that slows down a liver enzyme (called CYP3A4) that normally helps your body break down buprenorphine. When that enzyme is slowed, more buprenorphine builds up in your blood, so its effects can become stronger and last longer.
The main thing we watch for is too much sedation and slowed breathing. This is considered a serious interaction, so please don't stop or change either medicine on your own. The good news is your care team can handle this safely by adjusting your buprenorphine dose and watching you a bit more closely. Let your pharmacist or doctor know you take both.
Mechanism: Fosamprenavir inhibits CYP3A4, reducing buprenorphine metabolism and increasing buprenorphine exposure (higher plasma concentrations). Neither agent's activity here depends on prodrug conversion relevant to this pathway; the net effect is increased buprenorphine effect.
Effect: Prolonged opioid effects, including sedation and respiratory depression. Severity major; evidence probable; onset unspecified.
- If starting fosamprenavir in a buprenorphine patient, consider reducing buprenorphine dose until stable; monitor frequently for sedation/respiratory depression.
- On fosamprenavir discontinuation, consider increasing buprenorphine dose; monitor for withdrawal.
- For subQ (Sublocade/Brixadi) patients, monitor for over-medication; if precise titration is needed, transition to a formulation allowing finer dose adjustment.
What happens
Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
Combining buprenorphine with a CYP3A4 inhibitor can raise buprenorphine plasma levels, which may lead to extended opioid effects such as respiratory depression. When a patient on buprenorphine must also receive a CYP3A4 inhibitor, it may be appropriate to lower the buprenorphine dose until drug effects stabilize, while frequently watching for sedation and respiratory depression. Conversely, if a CYP3A4 inhibitor is stopped in someone taking buprenorphine, a buprenorphine dose increase may be warranted until stable drug effects are reached, with monitoring for opioid withdrawal signs2. Should the dose be impossible to adjust once the CYP3A4 inhibitor is removed, the patient should be switched back to a buprenorphine formulation that allows finer dose control. For patients moved from transmucosal buprenorphine given together with CYP3A4 inhibitors, confirm through monitoring that the buprenorphine plasma level delivered by subQ buprenorphine is sufficient. In those already receiving subQ buprenorphine who then need a CYP3A4 inhibitor, watch for indications of over-medication. If buprenorphine toxicity or overdose signs and symptoms appear and the co-administered drug cannot be lowered or stopped, decrease the buprenorphine dose. When the available doses do not allow the target dose to be reached, stop the treatment and manage the patient with a buprenorphine formulation that enables more precise dose adjustments 1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. Because fosamprenavir can raise your buprenorphine levels, your team may:
- Adjust and individualize your buprenorphine dose while things settle out.
- Monitor you more closely for excess drowsiness or slowed breathing.
- Watch for withdrawal symptoms if the fosamprenavir is later stopped, since your buprenorphine dose may then need to go back up.
- For long-acting injectable buprenorphine, watch for signs of over-medication and, if needed, switch to a form that allows finer dose changes.
Call your prescriber or pharmacist right away if you notice unusual sleepiness, confusion, or breathing that feels slow or shallow.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) Studies have not examined how CYP3A4 inhibitors administered together affect buprenorphine exposure in individuals receiving subQ buprenorphine; nonetheless, these interactions have been confirmed in investigations that employed transmucosal buprenorphine. Buprenorphine's effects may vary according to the route by which it is administered 1.
Common questions
Can I take Fosamprenavir and Buprenorphine together?
Fosamprenavir can raise buprenorphine levels and increase sedation and slowed breathing; keep taking both as prescribed and let your care team adjust the dose and monitor you closely. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Fosamprenavir and Buprenorphine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Fosamprenavir and Buprenorphine interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. Because fosamprenavir can raise your buprenorphine levels, your team may: Adjust and individualize your buprenorphine dose while things settle out. Monitor you more closely for excess drowsiness or slowed breathing. Watch for withdrawal symptoms if the fosamprenavir is later stopped, since your buprenorphine dose m… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Questions for your pharmacist
- Does my dose of Fosamprenavir or Buprenorphine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Fosamprenavir
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist